DekaBank Deutsche Girozentrale Boosts Holdings in Edwards Lifesciences Corporation (NYSE:EW)

DekaBank Deutsche Girozentrale raised its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 12.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,961,209 shares of the medical research company's stock after purchasing an additional 214,041 shares during the period. DekaBank Deutsche Girozentrale owned 0.33% of Edwards Lifesciences worth $137,624,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of EW. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences during the fourth quarter worth about $26,000. Vega Investment Solutions purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $27,000. Rossby Financial LCC purchased a new stake in Edwards Lifesciences during the first quarter worth about $29,000. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $29,000. Finally, Global X Japan Co. Ltd. increased its stake in shares of Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $0.15 during trading on Tuesday, hitting $76.84. 206,359 shares of the company traded hands, compared to its average volume of 5,223,252. The stock has a market capitalization of $45.08 billion, a price-to-earnings ratio of 10.97, a PEG ratio of 3.86 and a beta of 1.11. The business's fifty day moving average is $76.14 and its 200-day moving average is $73.29. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a one year low of $58.93 and a one year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter in the prior year, the business posted $0.66 earnings per share. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the topic of several research reports. Piper Sandler raised their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. Finally, Robert W. Baird upped their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research report on Thursday, April 24th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $80.40.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 2,570 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $77.40, for a total value of $198,918.00. Following the completion of the transaction, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total value of $112,620.00. Following the sale, the vice president directly owned 33,496 shares of the company's stock, valued at approximately $2,514,879.68. The trade was a 4.29% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 40,348 shares of company stock worth $2,977,683. 0.34% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.